View Older Stories View More Recent Stories
-
Deerfield Management Welcomes Frank Nestle, MD, FMedSci, as Partner and Chief Executive Officer of Therapeutic Discovery and Development
-
Cohere Health, Medical Mutual, and Rhyme Partner on Utilization Management Transformation
-
Form 4 Larimar Therapeutics, For: May 29 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Cure® Unveils US Biotech Industry Benchmark Report 2024: Dark Days of 2023 are Over
-
Adela to Present Data Supporting Use of its Tissue-Agnostic MRD Assay for Recurrence Prediction and Monitoring in Patients with Head & Neck Cancer at the American Society of Clinical Oncology 2024
-
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
-
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
-
Meditrina Announces 510(k) Clearance for Gen 2 Bipolar RF Hysteroscopy System and Aveta Glo Bipolar RF Device
-
Element Science Appoints Lee Smith, Jr. as the Company’s First Head of Commercial
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Cohere Health Launches Early Trend Signal Intelligence to Predict Utilization Trends Earlier than Claims-based Methods
-
One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)
-
Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
-
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
-
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-
Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of American Society of Hematology (ASH) Peter Steelman Scholar Award
-
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
-
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
-
MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization
-
MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization
-
Lumeris Completes $100M Equity Growth Capital Investment Round
-
Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
-
Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
-
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
-
CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000
-
Adela Presents Data Demonstrating Ability of Tissue-Agnostic MRD Assay to Predict Recurrence in Head & Neck Cancer at the American Association for Cancer Research Annual Meeting 2024
-
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
-
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Nkarta (NKTX) Prices $240M Share and Warrant Offering at $10/sh
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
Form 4 BiomX Inc. For: Mar 15 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 3 BiomX Inc. For: Mar 15 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
-
Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
-
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
-
Ventyx Biosciences (VTYX) Prices 11.17M Share Offering at $8.95/sh
-
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
-
BiomX (PHGE) and Adaptive Phage Therapeutics to Merge, Enter $50M Financing
-
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
Endologix Appoints Mike Mathias as Chief Commercial Officer
-
Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study
-
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
-
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
-
MMI Raises $110 Million in Series C Financing
-
Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
